Now showing items 1-5 of 5

    • Functional imaging and circulating biomarkers of response to regorafenib in treatment-refractory metastatic colorectal cancer patients in a prospective phase II study. 

      Khan, K; Rata, M; Cunningham, D; Koh, D-M; Tunariu, N; Hahne, JC; Vlachogiannis, G; Hedayat, S; Marchetti, S; Lampis, A; Damavandi, MD; Lote, H; Rana, I; Williams, A; Eccles, SA; Fontana, E; Collins, D; Eltahir, Z; Rao, S; Watkins, D; Starling, N; Thomas, J; Kalaitzaki, E; Fotiadis, N; Begum, R; Bali, M; Rugge, M; Temple, E; Fassan, M; Chau, I; Braconi, C; Valeri, N (2018-08)
      OBJECTIVE: Regorafenib demonstrated efficacy in patients with metastatic colorectal cancer (mCRC). Lack of predictive biomarkers, potential toxicities and cost-effectiveness concerns highlight the unmet need for better ...
    • Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. 

      Khan, KH; Cunningham, D; Werner, B; Vlachogiannis, G; Spiteri, I; Heide, T; Mateos, JF; Vatsiou, A; Lampis, A; Damavandi, MD; Lote, H; Huntingford, IS; Hedayat, S; Chau, I; Tunariu, N; Mentrasti, G; Trevisani, F; Rao, S; Anandappa, G; Watkins, D; Starling, N; Thomas, J; Peckitt, C; Khan, N; Rugge, M; Begum, R; Hezelova, B; Bryant, A; Jones, T; Proszek, P; Fassan, M; Hahne, JC; Hubank, M; Braconi, C; Sottoriva, A; Valeri, N (2018-10)
      Sequential profiling of plasma cell-free DNA (cfDNA) holds immense promise for early detection of patient progression. However, how to exploit the predictive power of cfDNA as a liquid biopsy in the clinic remains unclear. ...
    • miR-31-3p Expression and Benefit from Anti-EGFR Inhibitors in Metastatic Colorectal Cancer Patients Enrolled in the Prospective Phase II PROSPECT-C Trial. 

      Anandappa, G; Lampis, A; Cunningham, D; Khan, KH; Kouvelakis, K; Vlachogiannis, G; Hedayat, S; Tunariu, N; Rao, S; Watkins, D; Starling, N; Braconi, C; Darvish-Damavandi, M; Lote, H; Thomas, J; Peckitt, C; Kalaitzaki, R; Khan, N; Fotiadis, N; Rugge, M; Begum, R; Rana, I; Bryant, A; Hahne, JC; Chau, I; Fassan, M; Valeri, N (2019-07-01)
      PURPOSE: Anti-EGFR mAbs are effective in the treatment of metastatic colorectal cancer (mCRC) patients. RAS status and tumor location (sidedness) are predictive markers of patients' response to anti-EGFR mAbs. Recently, ...
    • Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. 

      Vlachogiannis, G; Hedayat, S; Vatsiou, A; Jamin, Y; Fernández-Mateos, J; Khan, K; Lampis, A; Eason, K; Huntingford, I; Burke, R; Rata, M; Koh, D-M; Tunariu, N; Collins, D; Hulkki-Wilson, S; Ragulan, C; Spiteri, I; Moorcraft, SY; Chau, I; Rao, S; Watkins, D; Fotiadis, N; Bali, M; Darvish-Damavandi, M; Lote, H; Eltahir, Z; Smyth, EC; Begum, R; Clarke, PA; Hahne, JC; Dowsett, M; de Bono, J; Workman, P; Sadanandam, A; Fassan, M; Sansom, OJ; Eccles, S; Starling, N; Braconi, C; Sottoriva, A; Robinson, SP; Cunningham, D; Valeri, N (2018-02-23)
      Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from ...
    • Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer. 

      Wagner, S; Vlachogiannis, G; De Haven Brandon, A; Valenti, M; Box, G; Jenkins, L; Mancusi, C; Self, A; Manodoro, F; Assiotis, I; Robinson, P; Chauhan, R; Rust, AG; Matthews, N; Eason, K; Khan, K; Starling, N; Cunningham, D; Sadanandam, A; Isacke, CM; Kirkin, V; Valeri, N; Whittaker, SR (2019-03)
      Despite showing clinical activity in BRAF-mutant melanoma, the MEK inhibitor (MEKi) trametinib has failed to show clinical benefit in KRAS-mutant colorectal cancer. To identify mechanisms of resistance to MEKi, we employed ...